2019 is undoubtedly the year of gene editing. All three major gene editing biotechnology companies have kicked the year off with monumental studies. As the results of these experiments get published, … [Read more...] about Sangamo (NASDAQ: SGMO) Vs. CRISPR Therapeutics (NASDAQ: CRSP): The Best Gene Editing Stock
From designer babies to malaria-resistant mosquitoes, a future where humans can dive into the basic building blocks of all life and manipulate it for our advantage is not too far away. Startups, … [Read more...] about Illumina: Growth at a Fair Price?